Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34463562 | 0.92 | L3MBTL1 (0.50) | L3MBTL1POLBNAMPTLMNATPSAB1 | |
| SCHEMBL1970601 | 0.83 | L3MBTL1 (0.56) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL12436973 | 0.82 | NAMPT (0.53) | L3MBTL1NAMPTNPC1SMN1; SMN2TPSAB1 | |
| SCHEMBL6526595 | 0.81 | ALDH1A1 (0.56) | L3MBTL1POLBLMNAMAPTITGB3 | |
| SCHEMBL25512563 | 0.81 | NAMPT (0.51) | L3MBTL1NAMPTNPC1SMN1; SMN2TPSAB1 | |
| SCHEMBL3919258 | 0.79 | L3MBTL1 (0.49) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL6974124 | 0.79 | L3MBTL1 (0.56) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL3711838 | 0.79 | NAMPT (0.56) | L3MBTL1NAMPTSMN1; SMN2TPSAB1TPSD1 | |
| SCHEMBL16761944 | 0.78 | NAMPT (0.51) | NAMPTNPC1TPSAB1TPSD1TPSG1 | |
| SCHEMBL4259604 | 0.78 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102498099-B | HSL inhibitors useful in the treatment of diabetes | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-29 | — | — | CN | claimed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| CN-102498099-A | HSL inhibitors useful in the treatment of diabetes | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| US-20260102383-A1 | LPAR1 Inhibitors | ABBVIE INC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-102498099-B | HSL inhibitors useful in the treatment of diabetes | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-29 | — | — | CN | disclosed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| CN-102498099-A | HSL inhibitors useful in the treatment of diabetes | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102383-A1 | LPAR1 Inhibitors | LPAR1, LPAR6, LPAR2 | L3MBTL1 1820/4885POLB 3296/4885NAMPT 3023/4885 |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | L3MBTL1 503/4885POLB 4833/4885NAMPT 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.